View : 28 Download: 0

A second dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-old children: a phase III, observer-blind, randomized, safety and immunogenicity study comparing GSK MMR and MMR II with and without DTaP-IPV and varicella vaccines co-administration

Title
A second dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-old children: a phase III, observer-blind, randomized, safety and immunogenicity study comparing GSK MMR and MMR II with and without DTaP-IPV and varicella vaccines co-administration
Authors
Huang Yhu-CheringJo, Dae SunKim, Chun SooKim, Hwang MinKim, Kwang-NamKim, Kyung-HyoKim, Yun-KyungKlein, Nicola P.Ma, Sang-HyukPeltier, ChristopherSenders, ShellyShepard, JulieWu, Tsung ZuYeh, Shu JenZissman, EdwardGillard, PaulPovey, MichaelAbu-Elyazeed, RemonHenry, OuzamaMMR-158 Study GrpChiu Nan-ChangClifford, RobertHuang Li-Min
Ewha Authors
김경효
SCOPUS Author ID
김경효scopus
Issue Date
2019
Journal Title
HUMAN VACCINES & IMMUNOTHERAPEUTICS
ISSN
2164-5515JCR Link

2164-554XJCR Link
Citation
HUMAN VACCINES & IMMUNOTHERAPEUTICS vol. 15, no. 4, pp. 786 - 799
Keywords
Measles-mumps-rubella vaccineDTaP-IPVvaricella vaccineimmunogenicitysafetyco-administration
Publisher
TAYLOR &

FRANCIS INC
Indexed
SCIE; SCOPUS WOS
Document Type
Article
Abstract
In many countries, a second dose of a combined measles, mumps, and rubella (MMR) vaccine is recommended at 4-6 years of age - similarly to the booster of diphtheria, tetanus, acellular pertussis, and inactivated polio vaccine (DTaP-IPV) and the second dose of varicella vaccine (VV). Vaccine co-administration is generally encouraged if no interferences exist among the vaccines. This phase IIIa, randomized, controlled trial (NCT01621802) evaluated the immunogenicity and safety of MMR-RIT (Priorix, GSK) when given as a second dose with or without co-administration of DTaP-IPV and VV, using MMR II (M-M-R II, Merck & Co Inc.) as comparator. Antibody geometric mean concentrations or titers (GMCs/GMTs) and response rates to the components of all the administered vaccines were assessed. Solicited, unsolicited, and serious adverse events were recorded. Four thousand eleven children aged 4-6 years were enrolled. MMR-RIT elicited immune responses that were not inferior to those of MMR II in terms of GMCs and seroresponse rates when administered alone or when co-administered with DTaP-IPV and VV. The immune responses to the co-administered vaccines in MMR-RIT recipients were non-inferior to those in MMR II recipients. MMR-RIT and MMR II demonstrated similar reactogenicity profiles; the most frequent solicited adverse events across vaccine groups and sub-cohorts were local pain and fever. In conclusion, the immunogenicity and safety profiles of MMR-RIT administered with or without DTaP-IPV and VV were similar to those of MMR II.
DOI
10.1080/21645515.2018.1554971
Appears in Collections:
의과대학 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE